Amlodipine/simvastatin

Drug Profile

Amlodipine/simvastatin

Alternative Names: Fixed-dose combination of delayed-release amlodipine and immediate-release simvastatin - HanAll Biopharma; HL-007; Simvastatin/amlodipine - HanAll Biopharma

Latest Information Update: 06 Aug 2015

Price : $50

At a glance

  • Originator HanAll Biopharma
  • Class Antihyperlipidaemics; Antihypertensives; Dihydropyridines; Naphthalenes
  • Mechanism of Action Calcium channel antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Hyperlipidaemia; Hypertension

Most Recent Events

  • 04 Aug 2015 No recent reports on development identified - Preclinical for Hyperlipidaemia in USA (PO)
  • 04 Aug 2015 No recent reports on development identified - Preclinical for Hypertension in USA (PO)
  • 04 Aug 2015 No recent reports on development identified - Phase-II for Hypertension in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top